Halozyme Therapeutics competitorsClear all
Agenus's top competitors include Blueprint Medicines.
 Agenus Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. |  Blueprint Medicines Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers. | |
Founding Date | Founding Date 1994 | Founding Date 2011 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Lexington, US HQ Cambridge, GB Berkeley, US New York, US | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH Cambridge, US |
Employees | Employees 32812% increase | Employees 38376% increase |
Valuation ($) | Valuation ($) 523.9 m | Valuation ($) 3.1 b |
Twitter followers | Twitter followers 2.3 k | Twitter followers 2.6 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 11 | Number of tweets (last 30 days) 14 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 8.8 | Average likes per tweet (last 30 days) 6.4 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% |
Alexa Website Rank | Alexa Website Rank 479547 | Alexa Website Rank 365252 |
Employee Rating | Employee Rating 3.2 | Employee Rating 4.2 |
Financial | ||
Revenue (est.) | Revenue (est.) $88.2m (FY, 2020) | Revenue (est.) $793.7m (FY, 2020) |
Cost of goods | Cost of goods $2.3m (FY, 2020) | Cost of goods $425k (FY, 2020) |
Gross profit | Gross profit $85.8m (FY, 2020) | Gross profit $793.3m (FY, 2020) |
Net income | Net income ($182.9m) (FY, 2020) | Net income $313.9m (FY, 2020) |
Funding | ||
Total funding raised | Total funding raised $ 171.1m | Total funding raised $ 115m |
For sources of this data, please see the company profile
View company profiles
Blueprint Medicines
HQ
Cambridge, US
Employees
383
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
View company